Status:

COMPLETED

Esomeprazole and Gastric Emptying of Beer

Lead Sponsor:

Heidelberg University

Conditions:

Gastroesophageal Reflux

Heartburn

Eligibility:

MALE

18-65 years

Phase:

PHASE4

Brief Summary

To investigate the effect of 20 mg esomeprazole daily for one week on gastric emptying of 500 ml beer, the consecutive blood alcohol levels, the gastroesophageal reflux and plasma levels of gastrin an...

Detailed Description

Sixteen healthy, male and non-smoking volunteers will be enrolled in this study. The subjects will be treated with placebo or with 20 mg esomeprazole daily for one week before gastric emptying will be...

Eligibility Criteria

Inclusion

  • Male, non-smoking volunteers without regular medication or regular alcohol consumption will be included.
  • Before inclusion blood will be drawn and the following blood count, liver, pancreas, kidney, thyroid and coagulation parameters will be examined:
  • Creatinine (0.5 - 1.3 mg/dl),
  • Alc. Phosphatase (38 - 126 U/l),
  • GGT (0 - 85 U/l),
  • ALAT (0 - 50 U/l),
  • ASAT (0 - 37 U/l),
  • LDH (0 - 248 U/l),
  • Cholinesterase (\>7000 U/l),
  • Amylase (25 - 130 U/l),
  • Lipase (114 - 300 U/l),
  • Leucocytes (3,5 - 11.0 10E9/L),
  • Erythrocytes (4.0 - 5.9 10E12/L),
  • Hb (12.0 - 17.5 g/dl),
  • Ht (33 - 50%),
  • Platelets (145 - 440 10E9/L),
  • CrP (\< 10 mg/l),
  • TSH (0.4 - 5.0 mE/l),
  • fT4 (6 - 23 pmol/l),
  • INR (0.75 - 1.30),
  • PTT (15.0 - 33.0 sec.)
  • The results have to be within the physiological range (as given in parenthesis).
  • Moreover, volunteers have mentally to be able to understand the explanations concerning the study and follow to the instructions of the investigator.

Exclusion

  • Any acute or chronic disease,
  • Heartburn more than once weekly,
  • Alcohol consumption of more than 50 g ethanol-equivalent per week,
  • Smoking,
  • Known hypersensitivity against esomeprazole,
  • Benzimidazole or other ingredients of the medication,
  • Fructose-intolerance,
  • Glucose-galactose-malabsorption or saccharase-isomaltase-deficiency.

Key Trial Info

Start Date :

January 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2006

Estimated Enrollment :

16 Patients enrolled

Trial Details

Trial ID

NCT00472550

Start Date

January 1 2006

End Date

November 1 2006

Last Update

May 11 2007

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Dep. Medicine II, University Hospital Mannheim

Mannheim, Germany, 68167